Transfection is a process which involves the production of genetically modified cells with the utilization of foreign nucleic acid (DNA and RNA). Transfection is an essential equipment used in the investigation studies for gene function and the modulation of gene expression.
Market Dynamics:-
The Global transfection reagents and equipment market is driven by,
• The rising incidence of infectious diseases
• Increase in the R&D expenditure and research activities by the pharmaceutical and biotechnology companies.
• Technological advancements in transfection
• Increasing incidence of cancer, and the presence of various government initiatives.
Infectious diseases represent a significant health problem worldwide, both in terms of morbidity and mortality. A complex combination of environmental, pathogen, and host genetic factors plays a role in determining both susceptibility to microbes and the course of infection. According to CDC, in 2017, the number of visits to physician offices with infectious and parasitic diseases as the primary diagnosis are 15.5 million, and the number of emergency department visits with the infectious and parasitic infections as the primary diagnosis were 3.7 million. Also, the number of emergency department visits resulting in hospital admission with a principal hospital discharge diagnosis of infectious and parasitic diseases were 280,000. Thus, the rising incidence of infectious diseases is driving the market.
Further, in recent times, the biopharmaceutical industry has seen a significant patent cliff as several blockbuster biologics are facing patent expiration. Consequently, several companies have begun investing in the production of biosimilar alternatives to the off-patent biologics to overcome the threat of revenue loss. Hence, the patent cliff threat has significantly benefitted the market by spurring the adoption rate of transfection technology.
The presence of technological advancements in transfection are expected to boost the market. For instance, some of the advancements include CRISPR-CAS9, CAR-T, and Three Dimension (3D) Transfection Technology. Also, in August 2019, researchers of the Salk Institute have developed a new tool, named, dubbed SATI to edit the mouse genome, enabling the team to target a broad range of mutations and cell types. The new genome-editing technology could be expanded for use in a broad range of gene mutation conditions such as Huntington's disease and the rare premature aging syndrome. Further, according to a study published in July 2019, the researchers of Tufts University and the Chinese Academy of Sciences, have used lipid nanoparticles to deliver CRISPR/Cas9 gene-editing tools for the potential treatment of hyperlipidemia.
Rising incidence of cancer is one of the dominating factors, propelling the global transfection reagents and equipment market. For instance, According to WHO, cancer is the second leading cause of death worldwide, and is responsible for around 9.6 million deaths in 2018 and globally, about 1 in 6 deaths is only because of cancer. The International Agency for Research on Cancer has reported that there will be 413,000 new cases in the forecast period. Thus, the rising incidences of cancer are driving the market.
However, the high cost of transfection reagents and equipment, risk factors during insertion of the reagents, selective effectiveness and certain limitations of transfection reagents and cytotoxic effect associated with transfection technology are the major factors restraining the transfection reagents and equipment market.
The number of cells that can be effectively transfected by the methods, and the limited clinical and laboratory use, owing to the integration of viral vectors randomly into the genome producing significant bio-hazardous risks are some of the limitations offered by the transfection reagents.
Market Segmentation:-
The reagents segment is sub-segmented into:
• Lipid-mediated transfection
• DEAE-dextran
• Activated dendrimers
• Calcium phosphate
• Cationic polymers
• Others
The reagents segment is expected to dominate the market over the forecast period. This is owing to the increasing commercial adoption rates of these reagents. For instance, OZ Biosciences revolutionized the Polyfection with the design of Helix-IN, a novel patented Cationic Hydroxylated Amphiphilic Multi-block Polymer (CHAMP Technology). This novel bi-functional co-polymer is biocompatible, ionizable, pH-responsive, and biodegradable. Thus, the increased adoption of reagents owing to the presence of products are driving the market.
Transfection equipment can be sub-segmented into:
• Liposomes
• Electroporation
• Microinjection
• Laserfection
• Others
Rapidly growing volume of genomics-based research and development initiatives and the introduction of user-friendly products like portable DNA sequencers are expected to propel the transfection reagent and equipment market during the forecast period. Owing to the presence of expensive laser-based equipment used for the different transfection methods like laserfection or optoinjection are estimated to drive the growth of the equipment segment.
Electroporation segment is expected to boost the market over the forecast period. Extensive portfolios for a range of electroporation products offered by the major and the emerging players are stimulating the growth of the segment. Moreover, several advantages provided by the method like the ease of use, variability, and timeliness are escalating the growth of the segment. For instance, on November 09, 2018 CRISPR Therapeutics and MaxCyte announced the expansion of the existing relationship by entering into a non-exclusive commercial license agreement which allows the CRISPR Therapeutics to deploy the MaxCyte’s Flow Electroporation® Technology to develop CRISPR/Cas9-based therapies in immuno-oncology. Thus, the presence of extensive product portfolios and the added advantages of the electroporation are driving the market.
By application, the transfection reagents and equipment market can be segmented into:
• Biomedical research
• Protein production
• Therapeutic delivery
Biomedical research is further sub-segmented into:
• Gene expression studies
• Cancer research
• Transgenic models
Biomedical research is expected to boost the market over the forecast period, owing to the increased adoption of reagents for biomedical research. For instance, AltoFect of Altogen biosystems transfection reagent enables the researchers to overcome the challenges and limitations related to primary cells and difficult-to-transfect cell lines. Also, Gene expression studies were expected to be the most prominent application. Expansion of genomic data pool and the growing emphasis on the translation of genomic information in the clinical workflow are leading to a considerable share of this segment. Presence of a substantial number of ongoing research projects that aim at the in-depth investigation of key mechanism, which underlies chromosomal anomalies, is also supplementing the growth of the segment.
Therapeutic delivery is expected to boost the market over the forecast period, owing to the increased adoption of reagents for the therapeutic delivery. In May 2019, Altogen Biosystems announced the launch of real-time adaptive cGMP manufacturing of liver-targeted in vivo transfection reagent. This new product enables dose, formulation, and product changes within a clinical protocol in response to the emerging clinical data as well as targeted delivery to hepatocellular carcinoma cells and increased in vivo stability of cargo therapeutics. This novel liver-targeted delivery system may enable groundbreaking transfection efficiency medical applications, including gene and oligonucleotides therapy of liver cancers. Thus, the growing adoption of transfection reagents for therapeutic delivery is driving the market.
North America is dominating the global transfection reagents and equipment market in 2018 and estimated to hold significant market size over the forecast period (2019-2026) owing to the rising incidence of various cancers, the increasing demand for proteomics and genomics technology and the upfront initiatives taken by the government related to preventive healthcare.
The rising incidence of cancer is expected to boost the market. For instance, according to the National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the US, and 609,640 people died from the disease. Thus, the growing number of cancer cases are driving the market.
The presence of upfront initiatives taken by the government related to preventive healthcare is expected to boost the market. For instance, the American cancer society has invested more than $4.8 billion in cancer research, to find more and better treatments, uncover factors that may cause cancer, and improve cancer patients' quality of life. Also, the National Cancer Institute coordinated the National Cancer Program, which conducts and supports the research, health information dissemination, and other programs related to the prevention, cause, diagnosis, and the treatment of cancer, rehabilitation from cancer, and the continuous care of cancer patients. Thus, the presence of government initiatives for preventive healthcare are driving the market.
Funding and the federal agencies, like the National Science Foundation (NSF), are offering the biotechnology sector with huge funding to carry out the biotechnology-based investigational studies. Moreover, the international funding bodies like NIH and Welcome Trust are expected to play a vital role in the market growth by giving the funds for genetic research studies.
Competitive Landscape:-
The key players operating in the global transfection reagents and equipment market are:
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• Agilent Technologies
• Illumina, Inc.
• Norgen Biotek Corp.
• QIAGEN, PerkinElmer Inc.
The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the transfection reagents and equipment market globally.
Key Takeaways:
• On December 13, 2018, Polyplus-transfection SA, announced the launch of PEIpro-GMP, a transfection reagent designed for the clinical and the commercial lentivirus and adeno-associated virus (AAV) production of cell & gene therapies.
• On May 22, 2018, Altogen Biosystems announced the launch of AltoFect, the second-generation transfection reagent for primary cell types and hard-to-transfect cell lines.
• In 2016, FormuMax Scientific, Inc., has launched the Trans-HiTM, as a superior transfection reagent to compete against the leading products in the market. Trans-HiTM is created based on proprietary polymer technology. It forms stable complex particles with DNA and rapidly releases the DNA molecules upon endocytosis into the cytoplasm.
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions. We monitor and analyze the market by dissecting various parameters such as market influencers, competitive intensity, innovations, trends, and emerging products.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
